Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
SABESP Announces Tariff Readjustment
SABESP's Net Income Grows 29.1% in 2Q09
The Public Attorney's Office of the State of Sao Paulo Requires Additional Time to Issue Its Final Interpretation of the Calculation and Eligibility Criteria Applicable to the Retirement and Pension Benefits Paid by SABESP on Behalf of the State of Sao Paulo
SemBioSys announces agreement with Avrio Ventures Limited Partnership and Botaneco
SemBioSys awarded key U.S. patent for the production of insulin in plants
SemBioSys announces non-binding letter of intent with Avrio Ventures Limited Partnership and Botaneco
SABESP Has Delayed in Filing Its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2008
Sabesp Announces 3rd Issue of Promissory Notes
SABESP's Net Operating Revenue Grows 7.4% in 1Q09
SABESP Announces Dividend Payment in the Form of Interest on Own Capital
SemBioSys provides update on insulin program - PR Newswire
SemBioSys provides update on insulin program - CNW
SABESP'S Net Operating Revenue Grows 6.4% in 2008
SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
SemBioSys announces 2008 financial and operational results
Botaneco receives additional milestone payments from AVAC Ltd.
Sabesp Announces Dividend Payment in the Form of Interest on Own Capital - Jan 16 2009 5:51PM
SemBioSys announces senior management changes
SemBioSys announces senior management changes
SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
SemBioSys receives US$2.5 million in option agreement with MannKind for plant-produced insulin
SemBioSys receives US$2.5 million in option agreement with MannKind for plant-produced insulin
SemBioSys begins phase I/II trial of insulin produced in plant seeds
SemBioSys begins phase I/II trial of insulin produced in plant seeds
Zacks Analyst Blog Highlights: Pfizer, Inc., Bristol-Myers Squibb Co., The Hershey Co., Kimberly Clark Corp. And Companhia De Saneamento Basico Do Estado De SãO Paulo
Zacks Analyst Blog Highlights: Pfizer, Inc., Bristol-Myers Squibb Co., The Hershey Co., Kimberly Clark Corp. And Companhia De Saneamento Basico Do Estado De Sao Paulo
Zacks Bull and Bear of the Day Highlights: SABESP, AutoNation, SiRF Technology, Public Storage and D.R. Horton
SABESP's Net Operating Revenue Grows 6.8% in 3Q08
Sabesp Executes Third Amendment to the GESP Agreement
SemBioSys announces third quarter 2008 financial and operational results
Zacks Analyst Blog Highlights: EOG Resources, Inc., Dr. Pepper Snapple Group Inc., Pepsi Bottling Group, Iconix Brand Group and Companhia De Saneamento Basico Do Estado De Sao Paulo.
SemBioSys announces substantial cost reductions to extend development runway
Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2
Botaneco receives natural ingredient approval from ECOCERT(R) for Hydresia(TM) G2
SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
Sabesp Announces Tariff Readjustment
SABESP's Net Revenue Grows 4.5% in 2Q08
SemBioSys announces second quarter 2008 financial and operational results
SemBioSys announces second quarter 2008 financial and operational results
Sabesp Announces Dividend Payment in the Form of Interest on Own Capital - Aug 1 2008 8:52PM
SemBioSys submits IND for safflower-produced insulin to U.S. FDA
Botaneco announces $4,000,000 financing
Botaneco announces $4,000,000 financing
SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
SABESP has Entered into a Confidentiality Agreement With EMAE
SemBioSys provides update on shrimp feed additive, Immunosphere(TM) - May 27 2008 12:55AM
SABESP'S Net Revenue Grows 5.2% in 1Q08 - May 27 2008 1:24AM
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia